


Amendments to the Claims:


This claim listing replaces all prior versions, and listings of claims in the application.
Please amend the claims as follows:

1. (Currently amended) Compounds of the general formula




(I)


wherein



is a group of one of the formulae



(a1)




(a2)



Applicants: Vrijbloed et al.

Application No. 10/530,335

Response to Restriction/Election Requirement dated June 16, 2009

Page 3





is the residue of an L- α -amino acid with B being a residue of formula $-\text{NR}^{20}\text{CH}(\text{R}^{71})-$ or the enantiomer of one of the groups **A1** to **A69** as defined hereinafter;




Applicants: Vrijbloed et al.

Application No. 10/530,335

Response to Restriction/Election Requirement dated June 16, 2009

Page 5

is a group of one of the formulae








Applicants: Vrijbloed et al.

Application No. 10/530,335

Response to Restriction/Election Requirement dated June 16, 2009

Page 6








Applicants: Vrijbloed et al.

Application No. 10/530,335

Response to Restriction/Election Requirement dated June 16, 2009

Page 7





Applicants: Vrijbloed et al.

Application No. 10/530,335

Response to Restriction/Election Requirement dated June 16, 2009

Page 8





R^1 is H; lower alkyl; or aryl-lower alkyl;

R^2 is H; alkyl; alkenyl; $-(CH_2)_m(CHR^{61})_sOR^{55}$; $-(CH_2)_m(CHR^{61})_sSR^{56}$;
 $-(CH_2)_m(CHR^{61})_sNR^{33}R^{34}$; $-(CH_2)_m(CHR^{61})_sOCONR^{33}R^{75}$;
 $-(CH_2)_m(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $-(CH_2)_o(CHR^{61})_sCOOR^{57}$;
 $-(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$;
 $-(CH_2)_o(CHR^{61})_sSO_2R^{62}$; or $-(CH_2)_o(CHR^{61})_sC_6H_4R^8$;

R^3 is H; alkyl; alkenyl; $-(CH_2)_m(CHR^{61})_sOR^{55}$; $-(CH_2)_m(CHR^{61})_sSR^{56}$;
 $-(CH_2)_m(CHR^{61})_sNR^{33}R^{34}$; $-(CH_2)_m(CHR^{61})_sOCONR^{33}R^{75}$;
 $-(CH_2)_m(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $-(CH_2)_o(CHR^{61})_sCOOR^{57}$;
 $-(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$;
 $-(CH_2)_o(CHR^{61})_sSO_2R^{62}$; or $-(CH_2)_o(CHR^{61})_sC_6H_4R^8$;








Applicants: Vrijbloed et al.

Application No. 10/530,335

Response to Restriction/Election Requirement dated June 16, 2009

Page 10

- R^4 is H; alkyl; alkenyl; $-(CH_2)_m(CHR^{61})_sOR^{55}$; $-(CH_2)_m(CHR^{61})_sSR^{56}$; $-(CH_2)_m(CHR^{61})_sNR^{33}R^{34}$; $-(CH_2)_m(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_m(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $-(CH_2)_p(CHR^{61})_sCOOR^{57}$; $-(CH_2)_p(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_p(CHR^{61})_sPO(OR^{60})_2$; $-(CH_2)_p(CHR^{61})_sSO_2R^{62}$; or $-(CH_2)_o(CHR^{61})_sC_6H_4R^8$;
- R^5 is alkyl; alkenyl; $-(CH_2)_o(CHR^{61})_sOR^{55}$; $-(CH_2)_o(CHR^{61})_sSR^{56}$; $-(CH_2)_o(CHR^{61})_sNR^{33}R^{34}$; $-(CH_2)_o(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_o(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $-(CH_2)_o(CHR^{61})_sCOOR^{57}$; $-(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$; $-(CH_2)_o(CHR^{61})_sSO_2R^{62}$; or $-(CH_2)_o(CHR^{61})_sC_6H_4R^8$;
- R^6 is H; alkyl; alkenyl; $-(CH_2)_o(CHR^{61})_sOR^{55}$; $-(CH_2)_o(CHR^{61})_sSR^{56}$; $-(CH_2)_o(CHR^{61})_sNR^{33}R^{34}$; $-(CH_2)_o(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_o(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $-(CH_2)_o(CHR^{61})_sCOOR^{57}$; $-(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$; $-(CH_2)_o(CHR^{61})_sSO_2R^{62}$; or $-(CH_2)_o(CHR^{61})_sC_6H_4R^8$;
- R^7 is alkyl; alkenyl; $-(CH_2)_q(CHR^{61})_sOR^{55}$; $-(CH_2)_q(CHR^{61})_sNR^{33}R^{34}$; $-(CH_2)_q(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_q(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $-(CH_2)_r(CHR^{61})_sCOOR^{57}$; $-(CH_2)_r(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_r(CHR^{61})_sPO(OR^{60})_2$; $-(CH_2)_r(CHR^{61})_sSO_2R^{62}$; or $-(CH_2)_r(CHR^{61})_sC_6H_4R^8$;
- R^8 is H; Cl; F; CF_3 ; NO_2 ; lower alkyl; lower alkenyl; aryl; aryl-lower alkyl; $-(CH_2)_o(CHR^{61})_sOR^{55}$; $-(CH_2)_o(CHR^{61})_sSR^{56}$; $-(CH_2)_o(CHR^{61})_sNR^{33}R^{34}$; $-(CH_2)_o(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_o(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $-(CH_2)_o(CHR^{61})_sCOOR^{57}$; $-(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$; $-(CH_2)_o(CHR^{61})_sSO_2R^{62}$; or $-(CH_2)_o(CHR^{61})_sCOR^{64}$;
- ~~R^9 is alkyl; alkenyl; $-(CH_2)_o(CHR^{61})_sOR^{55}$; $-(CH_2)_o(CHR^{61})_sSR^{56}$; $-(CH_2)_o(CHR^{61})_sNR^{33}R^{34}$; $-(CH_2)_o(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_o(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $-(CH_2)_o(CHR^{61})_sCOOR^{57}$; $-(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$; $-(CH_2)_o(CHR^{61})_sSO_2R^{62}$; or $-(CH_2)_o(CHR^{61})_sC_6H_4R^8$;~~
- ~~R^{10} is alkyl; alkenyl; $-(CH_2)_o(CHR^{61})_sOR^{55}$; $-(CH_2)_o(CHR^{61})_sSR^{56}$; $-(CH_2)_o(CHR^{61})_sNR^{33}R^{34}$;~~



R^{17} is alkyl; alkenyl; $-(CH_2)_q(CHR^{61})_sOR^{55}$; $-(CH_2)_q(CHR^{61})_sSR^{56}$; $-(CH_2)_q(CHR^{61})_sNR^{33}R^{34}$;
 $-(CH_2)_q(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_q(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;
 $-(CH_2)_q(CHR^{61})_sCOOR^{57}$; $-(CH_2)_q(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_q(CHR^{61})_sPO(OR^{60})_2$;
 $-(CH_2)_q(CHR^{61})_sSO_2R^{62}$; or $-(CH_2)_q(CHR^{61})_sC_6H_4R^8$;

R^{18} is alkyl; alkenyl; $-(CH_2)_p(CHR^{61})_sOR^{55}$; $-(CH_2)_p(CHR^{61})_sSR^{56}$; $-(CH_2)_p(CHR^{61})_sNR^{33}R^{34}$;
 $-(CH_2)_p(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_p(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;
 $-(CH_2)_p(CHR^{61})_sCOOR^{57}$; $-(CH_2)_p(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_p(CHR^{61})_sPO(OR^{60})_2$;
 $-(CH_2)_p(CHR^{61})_sSO_2R^{62}$; or $-(CH_2)_p(CHR^{61})_sC_6H_4R^8$;

R^{19} is lower alkyl; $-(CH_2)_p(CHR^{61})_sOR^{55}$; $-(CH_2)_p(CHR^{61})_sSR^{56}$; $-(CH_2)_p(CHR^{61})_sNR^{33}R^{34}$;
 $-(CH_2)_p(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_p(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;
 $-(CH_2)_p(CHR^{61})_sCOOR^{57}$; $-(CH_2)_p(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_p(CHR^{61})_sPO(OR^{60})_2$;
 $-(CH_2)_p(CHR^{61})_sSO_2R^{62}$; or $-(CH_2)_p(CHR^{61})_sC_6H_4R^8$; or

R^{18} and R^{19} taken together can form: $-(CH_2)_{2-6}$; $-(CH_2)_2O(CH_2)_2$; $-(CH_2)_2S(CH_2)_2$; or
 $-(CH_2)_2NR^{57}(CH_2)_2$;

R^{20} is H; alkyl; alkenyl; or aryl-lower alkyl;

R^{21} is H; alkyl; alkenyl; $-(CH_2)_6(CHR^{61})_sOR^{55}$; $-(CH_2)_6(CHR^{61})_sSR^{56}$;
 $-(CH_2)_6(CHR^{61})_sNR^{33}R^{34}$;
 $-(CH_2)_6(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_6(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;
 $-(CH_2)_6(CHR^{61})_sCOOR^{57}$; $-(CH_2)_6(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_6(CHR^{61})_sPO(OR^{60})_2$;
 $-(CH_2)_6(CHR^{61})_sSO_2R^{62}$; or $-(CH_2)_6(CHR^{61})_sC_6H_4R^8$;

R^{22} is H; alkyl; alkenyl; $-(CH_2)_6(CHR^{61})_sOR^{55}$; $-(CH_2)_6(CHR^{61})_sSR^{56}$;
 $-(CH_2)_6(CHR^{61})_sNR^{33}R^{34}$;
 $-(CH_2)_6(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_6(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;
 $-(CH_2)_6(CHR^{61})_sCOOR^{57}$; $-(CH_2)_6(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_6(CHR^{61})_sPO(OR^{60})_2$;
 $-(CH_2)_6(CHR^{61})_sSO_2R^{62}$; or $-(CH_2)_6(CHR^{61})_sC_6H_4R^8$;


R^{23} is alkyl; alkenyl; $-(CH_2)_6(CHR^{61})_sOR^{55}$; $-(CH_2)_6(CHR^{61})_sSR^{56}$; $-(CH_2)_6(CHR^{61})_sNR^{33}R^{34}$;
 $-(CH_2)_6(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_6(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;
 $-(CH_2)_6(CHR^{61})_sCOOR^{57}$; $-(CH_2)_6(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_6(CHR^{61})_sPO(OR^{60})_2$;

Applicants: Vrijbloed et al.




Application No. 10/530,335

Response to Restriction/Election Requirement dated June 16, 2009





Page 13






R^{24} is ~~alkyl; alkenyl; $-(\text{CH}_2)_6(\text{CHR}^{61})_5\text{OR}^{55}$; $-(\text{CH}_2)_6(\text{CHR}^{61})_5\text{SR}^{56}$; $-(\text{CH}_2)_6(\text{CHR}^{61})_5\text{NR}^{33}\text{R}^{34}$;~~



R^{25} is H; alkyl; alkenyl; $-(\text{CH}_2)_m(\text{CHR}^{61})_s\text{OR}^{55}$; $-(\text{CH}_2)_m(\text{CHR}^{61})_s\text{SR}^{56}$;







R^{26} is H; alkyl; alkenyl; $-(\text{CH}_2)_m(\text{CHR}^{61})_s\text{OR}^{55}$; $-(\text{CH}_2)_m(\text{CHR}^{61})_s\text{SR}^{56}$;






R^{25} and R^{26} taken together can form: $-(\text{CH}_2)_{2-6}-$; $-(\text{CH}_2)_r\text{O}(\text{CH}_2)_r-$; $-(\text{CH}_2)_r\text{S}(\text{CH}_2)_r-$; or




R^{27} is ~~H; alkyl; alkenyl; $-(\text{CH}_2)_6(\text{CHR}^{61})_5\text{OR}^{55}$; $-(\text{CH}_2)_6(\text{CHR}^{61})_5\text{SR}^{56}$;~~



R^{28} is ~~alkyl; alkenyl; $-(\text{CH}_2)_6(\text{CHR}^{61})_5\text{OR}^{55}$; $-(\text{CH}_2)_6(\text{CHR}^{61})_5\text{SR}^{56}$; $-(\text{CH}_2)_6(\text{CHR}^{61})_5\text{NR}^{33}\text{R}^{34}$;~~



R^{29} is ~~alkyl; alkenyl; $-(\text{CH}_2)_6(\text{CHR}^{61})_5\text{OR}^{55}$; $-(\text{CH}_2)_6(\text{CHR}^{61})_5\text{SR}^{56}$; $-(\text{CH}_2)_6(\text{CHR}^{61})_5\text{NR}^{33}\text{R}^{34}$;~~




Applicants: Vrijbloed et al.


Application No. 10/530,335

Response to Restriction/Election Requirement dated June 16, 2009


Page 14








R^{30} is ~~H; alkyl; alkenyl; or aryl-lower alkyl;~~



R^{32} is ~~H; lower alkyl; or aryl-lower alkyl;~~



R^{34} is H; lower alkyl; aryl, or aryl-lower alkyl;




Applicants: Vrijbloed et al.

Application No. 10/530,335









Response to Restriction/Election Requirement dated June 16, 2009

Page 15



R^{39} is ~~H; alkyl; alkenyl; or aryl-lower alkyl;~~

R^{40} is ~~H; alkyl; alkenyl; or aryl-lower alkyl;~~



Applicants: Vrijbloed et al.

Application No. 10/530,335

Response to Restriction/Election Requirement dated June 16, 2009

Page 16

R^{48} is ~~H; lower alkyl; lower alkenyl; or aryl-lower alkyl;~~

R^{49} is ~~H; alkyl; alkenyl; $(CHR^{61})_sCOOR^{57}$; $(CHR^{61})_sCONR^{58}R^{59}$; $(CHR^{61})_sPO(OR^{60})_2$;
 $(CHR^{61})_sSOR^{62}$; or $(CHR^{61})_sC_6H_4R^8$;~~

R^{50} is H; lower alkyl; or aryl-lower alkyl;

R^{51} is ~~H; alkyl; alkenyl; $(CH_2)_m(CHR^{61})_sOR^{55}$; $(CH_2)_m(CHR^{61})_sSR^{56}$;
 $(CH_2)_m(CHR^{61})_sNR^{33}R^{34}$; $(CH_2)_m(CHR^{61})_sOCONR^{33}R^{75}$;
 $(CH_2)_m(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $(CH_2)_o(CHR^{61})_sCOOR^{57}$;
 $(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $(CH_2)_o(CHR^{61})_pPO(OR^{60})_2$;
 $(CH_2)_p(CHR^{61})_sSO_2R^{62}$; or $(CH_2)_p(CHR^{61})_sC_6H_4R^8$;~~


R^{52} is ~~H; alkyl; alkenyl; $(CH_2)_m(CHR^{61})_sOR^{55}$; $(CH_2)_m(CHR^{61})_sSR^{56}$;
 $(CH_2)_m(CHR^{61})_sNR^{33}R^{34}$; $(CH_2)_m(CHR^{61})_sOCONR^{33}R^{75}$;
 $(CH_2)_m(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $(CH_2)_o(CHR^{61})_sCOOR^{57}$;
 $(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $(CH_2)_o(CHR^{61})_pPO(OR^{60})_2$;
 $(CH_2)_p(CHR^{61})_sSO_2R^{62}$; or $(CH_2)_p(CHR^{61})_sC_6H_4R^8$;~~

R^{53} is ~~H; alkyl; alkenyl; $(CH_2)_m(CHR^{61})_sOR^{55}$; $(CH_2)_m(CHR^{61})_sSR^{56}$;
 $(CH_2)_m(CHR^{61})_sNR^{33}R^{34}$;
 $(CH_2)_m(CHR^{61})_sOCONR^{33}R^{75}$;
 $(CH_2)_m(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $(CH_2)_o(CHR^{61})_sCOOR^{57}$;
 $(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $(CH_2)_o(CHR^{61})_pPO(OR^{60})_2$;
 $(CH_2)_p(CHR^{61})_sSO_2R^{62}$; or $(CH_2)_p(CHR^{61})_sC_6H_4R^8$;~~

R^{54} is ~~H; alkyl; alkenyl; $(CH_2)_m(CHR^{61})_sOR^{55}$; $(CH_2)_m(CHR^{61})_sNR^{33}R^{34}$;
 $(CH_2)_m(CHR^{61})_sOCONR^{33}R^{75}$; $(CH_2)_m(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;
 $(CH_2)_o(CHR^{61})_sCOOR^{57}$; $(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; or $(CH_2)_o(CHR^{61})_sC_6H_4R^8$;~~

R^{55} is H; lower alkyl; lower alkenyl; aryl-lower alkyl; $(CH_2)_m(CHR^{61})_sOR^{57}$;
 $(CH_2)_m(CHR^{61})_sNR^{34}R^{63}$; $(CH_2)_m(CHR^{61})_sOCONR^{75}R^{82}$;
 $(CH_2)_m(CHR^{61})_sNR^{20}CONR^{78}R^{82}$; $(CH_2)_o(CHR^{61})_sCOR^{64}$; $(CH_2)_o(CHR^{61})_sCOOR^{57}$; or
 $(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$;

R^{56} is H; lower alkyl; lower alkenyl; aryl-lower alkyl; $(CH_2)_m(CHR^{61})_sOR^{57}$;



R⁵⁷ is H; lower alkyl; lower alkenyl; aryl lower alkyl; or heteroaryl lower alkyl;

R⁵⁸ is H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; or heteroaryl-lower alkyl;

R⁵⁹ is H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; or heteroaryl-lower alkyl; or

R⁵⁸ and R⁵⁹ taken together can form: $-(\text{CH}_2)_{2-6}-$; $-(\text{CH}_2)_2\text{O}(\text{CH}_2)_2-$; $-(\text{CH}_2)_2\text{S}(\text{CH}_2)_2-$; or $-(\text{CH}_2)_2\text{NR}^{57}(\text{CH}_2)_2-$;

R⁶⁰ is H; lower alkyl; lower alkenyl; aryl; or aryl-lower alkyl;

R⁶¹ is alkyl; alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(\text{CH}_2)_m\text{OR}^{55}$; $-(\text{CH}_2)_m\text{NR}^{33}\text{R}^{34}$; $-(\text{CH}_2)_m\text{OCONR}^{75}\text{R}^{82}$; $-(\text{CH}_2)_m\text{NR}^{20}\text{CONR}^{78}\text{R}^{82}$; $-(\text{CH}_2)_o\text{COOR}^{37}$; $-(\text{CH}_2)_o\text{NR}^{58}\text{R}^{59}$; or $-(\text{CH}_2)_o\text{PO}(\text{COR}^{60})_2$;

R⁶² is lower alkyl; lower alkenyl; aryl, heteroaryl; or aryl-lower alkyl;

R⁶³ is H; lower alkyl; lower alkenyl; aryl, heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-\text{COR}^{64}$; $-\text{COOR}^{57}$; $-\text{CONR}^{58}\text{R}^{59}$; $-\text{SO}_2\text{R}^{62}$; or $-\text{PO}(\text{OR}^{60})_2$;

R³⁴ and R⁶³ taken together can form: $-(\text{CH}_2)_{2-6}-$; $-(\text{CH}_2)_2\text{O}(\text{CH}_2)_2-$; $-(\text{CH}_2)_2\text{S}(\text{CH}_2)_2-$; or $-(\text{CH}_2)_2\text{NR}^{57}(\text{CH}_2)_2-$;

R⁶⁴ is H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(\text{CH}_2)_p(\text{CHR}^{61})_s\text{OR}^{65}$; $-(\text{CH}_2)_p(\text{CHR}^{61})_s\text{SR}^{66}$; or $-(\text{CH}_2)_p(\text{CHR}^{61})_s\text{NR}^{34}\text{R}^{63}$; $-(\text{CH}_2)_p(\text{CHR}^{61})_s\text{OCONR}^{75}\text{R}^{82}$; $-(\text{CH}_2)_p(\text{CHR}^{61})_s\text{NR}^{20}\text{CONR}^{78}\text{R}^{82}$;

R⁶⁵ is H; lower alkyl; lower alkenyl; aryl, aryl-lower alkyl; heteroaryl-lower alkyl; $-\text{COR}^{57}$; $-\text{COOR}^{57}$; or $-\text{CONR}^{58}\text{R}^{59}$;

R⁶⁶ is H; lower alkyl; lower alkenyl; aryl; aryl-lower alkyl; heteroaryl-lower alkyl; or $-\text{CONR}^{58}\text{R}^{59}$;

m is 2-4; o is 0-4; p is 1-4; q is 0-2; r is 1 or 2; s is 0 or 1;

Z is a chain of 12 α -amino acid residues, the positions of said amino acid residues in said chain being counted starting from the N-terminal amino acid, whereby these amino acid residues are, depending on their position in the chains, Gly, or Pro, or of formula **-A-CO-**, or of formula **-B-CO-**, or of one of the types

C: $-\text{NR}^{20}\text{CH}(\text{R}^{72})\text{CO}-$;

D: $-\text{NR}^{20}\text{CH}(\text{R}^{73})\text{CO}-$;

E: $-\text{NR}^{20}\text{CH}(\text{R}^{74})\text{CO}-$;

F: $-\text{NR}^{20}\text{CH}(\text{R}^{84})\text{CO}-$; and

H: $-\text{NR}^{20}-\text{CH}(\text{CO}-)(\text{CH}_2)_{4-7}-\text{CH}(\text{CO}-)\text{NR}^{20}-$;
 $-\text{NR}^{20}-\text{CH}(\text{CO}-)(\text{CH}_2)_p\text{SS}(\text{CH}_2)_p-\text{CH}(\text{CO}-)\text{NR}^{20}-$;
 $-\text{NR}^{20}-\text{CH}(\text{CO}-)(-\text{CH}_2)_p\text{NR}^{20}\text{CO}(\text{CH}_2)_p-\text{CH}(\text{CO}-)\text{NR}^{20}-$; and
 $-\text{NR}^{20}-\text{CH}(\text{CO}-)(-\text{CH}_2)_p\text{NR}^{20}\text{CONR}^{20}(\text{CH}_2)_p-\text{CH}(\text{CO}-)\text{NR}^{20}-$;

I: $-\text{NR}^{86}\text{CH}_2\text{CO}-$;

K: $-\text{NR}^{87}\text{CH}_2\text{CO}-$;

R^{71} is H; lower alkyl; lower alkenyl; $-(\text{CH}_2)_p(\text{CHR}^{61})_s\text{OR}^{75}$; $-(\text{CH}_2)_p(\text{CHR}^{61})_s\text{SR}^{75}$;
 $-(\text{CH}_2)_p(\text{CHR}^{61})_s\text{NR}^{33}\text{R}^{34}$; $-(\text{CH}_2)_p(\text{CHR}^{61})_s\text{OCONR}^{33}\text{R}^{75}$; -
 $(\text{CH}_2)_p(\text{CHR}^{61})_s\text{NR}^{20}\text{CONR}^{33}\text{R}^{82}$;
 $-(\text{CH}_2)_0(\text{CHR}^{61})_s\text{COOR}^{75}$; $-(\text{CH}_2)_p\text{CONR}^{58}\text{R}^{59}$; $-(\text{CH}_2)_p\text{PO}(\text{OR}^{62})_2$; $-(\text{CH}_2)_p\text{SO}_2\text{R}^{62}$; or
 $-(\text{CH}_2)_6-\text{C}_6\text{R}^{67}\text{R}^{68}\text{R}^{69}\text{R}^{70}\text{R}^{76}$;

R^{72} is H, lower alkyl; lower alkenyl; $-(\text{CH}_2)_p(\text{CHR}^{61})_s\text{OR}^{85}$; or $-(\text{CH}_2)_p(\text{CHR}^{61})_s\text{SR}^{85}$;

R^{73} is $-(\text{CH}_2)_0\text{R}^{77}$; $-(\text{CH}_2)_t\text{O}(\text{CH}_2)_0\text{R}^{77}$; $-(\text{CH}_2)_t\text{S}(\text{CH}_2)_0\text{R}^{77}$; or $-(\text{CH}_2)_t\text{NR}^{20}(\text{CH}_2)_0\text{R}^{77}$;

R^{74} is $-(\text{CH}_2)_p\text{NR}^{78}\text{R}^{79}$; $-(\text{CH}_2)_p\text{NR}^{77}\text{R}^{80}$; $-(\text{CH}_2)_p\text{C}(=\text{NR}^{80})\text{NR}^{78}\text{R}^{79}$; -
 $(\text{CH}_2)_p\text{C}(=\text{NOR}^{50})\text{NR}^{78}\text{R}^{79}$;
 $-(\text{CH}_2)_p\text{C}(=\text{NNR}^{78}\text{R}^{79})\text{NR}^{78}\text{R}^{79}$; $-(\text{CH}_2)_p\text{NR}^{80}\text{C}(=\text{NR}^{80})\text{NR}^{78}\text{R}^{79}$;
 $-(\text{CH}_2)_p\text{N}=\text{C}(\text{NR}^{78}\text{R}^{80})\text{NR}^{79}\text{R}^{80}$; $-(\text{CH}_2)_p\text{C}_6\text{H}_4\text{NR}^{78}\text{R}^{79}$; $-(\text{CH}_2)_p\text{C}_6\text{H}_4\text{NR}^{77}\text{R}^{80}$;
 $-(\text{CH}_2)_p\text{C}_6\text{H}_4\text{C}(=\text{NR}^{80})\text{NR}^{78}\text{R}^{79}$; $-(\text{CH}_2)_p\text{C}_6\text{H}_4\text{C}(=\text{NOR}^{50})\text{NR}^{78}\text{R}^{79}$;
 $-(\text{CH}_2)_p\text{C}_6\text{H}_4\text{C}(=\text{NNR}^{78}\text{R}^{79})\text{NR}^{78}\text{R}^{79}$; $-(\text{CH}_2)_p\text{C}_6\text{H}_4\text{NR}^{80}\text{C}(=\text{NR}^{80})\text{NR}^{78}\text{R}^{79}$;

$-(CH_2)_pC_6H_4N=C(NR^{78}R^{80})NR^{79}R^{80}$; $-(CH_2)_rO(CH_2)_mNR^{78}R^{79}$; $-(CH_2)_rO(CH_2)_mNR^{77}R^{80}$;
 $-(CH_2)_rO(CH_2)_pC(=NR^{80})NR^{78}R^{79}$; $-(CH_2)_rO(CH_2)_pC(=NOR^{50})NR^{78}R^{79}$;
 $-(CH_2)_rO(CH_2)_pC(=NNR^{78}R^{79})NR^{78}R^{79}$; $-(CH_2)_rO(CH_2)_mNR^{80}C(=NR^{80})NR^{78}R^{79}$;
 $-(CH_2)_rO(CH_2)_mN=C(NR^{78}R^{80})NR^{79}R^{80}$; $-(CH_2)_rO(CH_2)_pC_6H_4CNR^{78}R^{79}$;
 $-(CH_2)_rO(CH_2)_pC_6H_4C(=NR^{80})NR^{78}R^{79}$; $-(CH_2)_rO(CH_2)_pC_6H_4C(=NOR^{50})NR^{78}R^{79}$;
 $-(CH_2)_rO(CH_2)_pC_6H_4C(=NNR^{78}R^{79})NR^{78}R^{79}$;
 $-(CH_2)_rO(CH_2)_pC_6H_4NR^{80}C(=NR^{80})NR^{78}R^{79}$; $-(CH_2)_rS(CH_2)_mNR^{78}R^{79}$;
 $-(CH_2)_rS(CH_2)_mNR^{77}R^{80}$; $-(CH_2)_rS(CH_2)_pC(=NR^{80})NR^{78}R^{79}$;
 $-(CH_2)_rS(CH_2)_pC(=NOR^{50})NR^{78}R^{79}$; $-(CH_2)_rS(CH_2)_pC(=NNR^{78}R^{79})NR^{78}R^{79}$;
 $-(CH_2)_rS(CH_2)_mNR^{80}C(=NR^{80})NR^{78}R^{79}$; $-(CH_2)_rS(CH_2)_mN=C(NR^{78}R^{80})NR^{79}R^{80}$;
 $-(CH_2)_rS(CH_2)_pC_6H_4CNR^{78}R^{79}$; $-(CH_2)_rS(CH_2)_pC_6H_4C(=NR^{80})NR^{78}R^{79}$;
 $-(CH_2)_rS(CH_2)_pC_6H_4C(=NOR^{50})NR^{78}R^{79}$; $-(CH_2)_rS(CH_2)_pC_6H_4C(=NNR^{78}R^{79})NR^{78}R^{79}$;
 $-(CH_2)_rS(CH_2)_pC_6H_4NR^{80}C(=NR^{80})NR^{78}R^{79}$; $-(CH_2)_pNR^{80}COR^{64}$; $-(CH_2)_pNR^{80}COR^{77}$;
 $-(CH_2)_pNR^{80}CONR^{78}R^{79}$; or $-(CH_2)_pC_6H_4NR^{80}CONR^{78}R^{79}$;

R^{75} is lower alkyl; lower alkenyl; or aryl-lower alkyl;

R^{33} and R^{75} taken together can form: $-(CH_2)_{2-6}$; $-(CH_2)_2O(CH_2)_2$; $-(CH_2)_2S(CH_2)_2$; or
 $-(CH_2)_2NR^{57}(CH_2)_2$;

R^{75} and R^{82} taken together can form: $-(CH_2)_{2-6}$; $-(CH_2)_2O(CH_2)_2$; $-(CH_2)_2S(CH_2)_2$; or
 $-(CH_2)_2NR^{57}(CH_2)_2$;

R^{76} is H; lower alkyl; lower alkenyl; aryl-lower alkyl; $-(CH_2)_oOR^{72}$; $-(CH_2)_oSR^{72}$;
 $-(CH_2)_oNR^{33}R^{34}$; $-(CH_2)_oOCONR^{33}R^{75}$; $-(CH_2)_oNR^{20}CONR^{33}R^{82}$;
 $-(CH_2)_oCOOR^{75}$; $-(CH_2)_oCONR^{58}R^{59}$; $-(CH_2)_oPO(OR^{60})_2$; $-(CH_2)_pSO_2R^{62}$; or
 $-(CH_2)_oCOR^{64}$;


R^{77} is $-C_6R^{67}R^{68}R^{69}R^{70}R^{76}$; is phenyl, p-hydroxyphenyl, 2-naphthyl, 1-naphthyl, 4-chlorophenyl,
3-chlorophenyl, 2-chlorophenyl, 3,4-dichlorophenyl, 4-fluorophenyl, 3-fluorophenyl, 2-
fluorophenyl, p-benzyloxyphenyl, p-biphenyl or p-benzoylphenyl or a heteroaryl group of one of
 the formulae

Applicants: Vrijbloed et al.


Application No. 10/530,335

Response to Restriction/Election Requirement dated June 16, 2009


Page 20




H1




H2




H3




H4




H5




H6




H7




H8




H9




H10




H11




H12




H13




H14




H15




H16




H17




H18




H19




H20




H21




H22




H23




H24




H25




H26




H27




H28




H29




H30



H31



H32




H33

Applicants: Vrijbloed et al.


Application No. 10/530,335

Response to Restriction/Election Requirement dated June 16, 2009


Page 21




H34




H35




H36




H37




H38




H39




H40




H41




H42




H43




H44




H45




H46




H47




H48




H49




H50




H51



H52



H53



H54

R^{78} is H; lower alkyl; aryl; or aryl-lower alkyl;

R^{78} and R^{82} taken together can form: $-(CH_2)_{2-6}-$; $-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$;

R^{79} is H; lower alkyl; aryl; or aryl-lower alkyl; or

Applicants: Vrijbloed et al.

Application No. 10/530,335

Response to Restriction/Election Requirement dated June 16, 2009

Page 22

R^{78} and R^{79} , taken together, can be $-(CH_2)_{2-7}-$; $-(CH_2)_2O(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$;

R^{80} is H; or lower alkyl;

R^{81} is H; lower alkyl; or aryl-lower alkyl;

R^{82} is H; lower alkyl; aryl; heteroaryl; or aryl-lower alkyl;

R^{33} and R^{82} taken together can form: $-(CH_2)_{2-6}-$; $-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$;

R^{83} is H; lower alkyl; aryl; or $-NR^{78}R^{79}$;

R^{84} is $-(CH_2)_m(CHR^{61})_sOR^{78}$; $-(CH_2)_m(CHR^{61})_sSR^{78}$; $-(CH_2)_pCONR^{78}R^{79}$; $-(CH_2)_pNR^{80}CONR^{78}R^{79}$; $-(CH_2)_pC_6H_4CONR^{78}R^{79}$; or $-(CH_2)_pC_6H_4NR^{80}CONR^{78}R^{79}$;

R^{85} is lower alkyl; or lower alkenyl;

R^{86} is R^{74} ; $-[(CH_2)_u-X]_t-(CH_2)_vNR^{78}R^{79}$; $-[(CH_2)_u-X]_t-(CH_2)_v-C(=NR^{80})NR^{78}R^{79}$; X is $-O-$, $-NR^{20}-$, $-S-$, $-OCOO-$, u is 1-3, t is 1-6, v is 1-3;

R^{87} is R^{84} ; $-[(CH_2)_u-X]_t-(CH_2)_vOR^{78}$, $-[(CH_2)_u-X]_t-(CH_2)_v-CONR^{78}R^{79}$, $-[(CH_2)_u-X]_t-(CH_2)_v-NR^{80}CONR^{78}R^{79}$, $-[(CH_2)_u-X]_t-(CH_2)_vSR^{78}$; X is $-O-$, $-NR^{20}-$, $-S-$, $-OCOO-$, u is 1-3, t is 1-6, v is 1-3;

with the proviso that in said chain of 12 α -amino acid residues **Z** the amino acid residues in positions 1 to 12 are:

- P1: of type C or of type D or of type E or of type F, or the residue is Pro;
- P2: of type E or of type D;
- P3: of type C, or the residue is Pro;
- P4: of type E or of type F or of type I or of type K;
- P5: of type E or of type D or or of type C or of type I or of type K or of type F, or the residue is Gly or Pro;
- P6: of type E or of type F or of formula $-A-CO-$, or of type I or of type K or of type D, or the residue is Gly;
- P7: of type E or of type F or of type I or of type C or of formula $-B-CO-$;

Applicants: Vrijbloed et al.

Application No. 10/530,335

Response to Restriction/Election Requirement dated June 16, 2009

Page 23

- P8: of type D or of type C, or the residue is Pro;
- P9: of type E or of type D or of type F ;
- P10: of type D or of type C or the residue is Pro;
- P11: of type E or of type D or of type C; and
- P12: of type C or of type D or of type E or of type F, or the residue is Pro; or
- P4 and P9 and/or P2 and P11, taken together, can form a group of type H; and at P6 and P7 also D-isomers being possible;

with the further proviso that said chain of 12 α -amino acid residues contains at least one residue of type I or of type K;


and pharmaceutically acceptable salts thereof.

2-9. (Cancelled)

10. (Currently amended) Compounds according to claim 2 wherein B is a group of formula $-\text{NR}^{20}\text{CH}(\text{R}^{71})-$ or an enantiomer of one of the groups A5 (with R^2 being H); or A8; A22; A25; A38 (with R^2 being H); A42; A47; and A50.

11. (Currently amended) Compounds according to claim 2 1 wherein B-CO is Ala; Arg; Asn; Cys; Gln; Gly; His; Ile; Leu; Lys; Met; Phe; Pro; Ser; Thr; Trp; Tyr; Val; Cit; Orn; tBuA; Sar; t-BuG; 4AmPhe; 3AmPhe; 2AmPhe; Phe(mC(NH₂)=NH; Phe(pC(NH₂)=NH; Phe(mNHC(NH₂)=NH; Phe(pNHC(NH₂)=NH; Phg; Cha; C₄al; C₅al; Nle; 2-Nal; 1-Nal; 4Cl-Phe; 3Cl-Phe; 2Cl-Phe; 3,4Cl₂Phe; 4F-Phe; 3F-Phe; 2F-Phe; Tic; Thi; Tza; Mso; AcLys; Dpr; A₂Bu; Dbu; Abu; Aha; Aib; Y(Bzl); Bip; S(Bzl); T(Bzl); hCha; hCys; hSer; hArg; hPhe; Bpa; Pip; OctG; MePhe; MeNle; MeAla; Melle; MeVal; MeLeu; BnG; (4-OH)BnG; IaG; IbG; (EA)G; (PrA)G; (BA)G; (PeA)G; (EGU)G; (PrGU)G; (BGU)G; (PeGU)G; (PEG₃-NH₂)G; (Et-CONH₂)G; (Et-OH)G; (CH₂-CONH₂)G; (n-Pr-NHCONH₂)G; or (Et-SH)G.

12. (Currently amended) Compounds according to claim 2 1 wherein B is a group, having (L)-configuration, of formula



wherein R^{20} is H; or lower alkyl; and R^{64} is alkyl; alkenyl; aryl; aryl-lower alkyl; or heteroaryl-lower alkyl.

13. (Original) Compounds according to claim 12 wherein R^{64} is n-hexyl; n-heptyl; 4-(phenyl)benzyl; diphenylmethyl, 3-amino-propyl; 5-amino-pentyl; methyl; ethyl; isopropyl; isobutyl; n-propyl; cyclohexyl; cyclohexylmethyl; n-butyl; phenyl; benzyl; (3-indolyl)methyl; 2-(3-indolyl)ethyl; (4-phenyl)phenyl; or n-nonyl.

14-15. (Cancelled)

16. (Previously presented) Compounds according to claim 1 wherein the α -amino acid residues in position 1 – 12 of chain Z are:

- P1: of type C or of type D or of type E or of type F,
- P2: of type D or of type E;
- P3: of type C;
- P4: of type E or of type I or of type F;
- P5: of type E or of type I or of type F;
- P6: of type E or of type I or of type D or of formula -A1-A69-CO;
- P7: of type E or of type I or of type C or of formula B-CO;
- P8: of type D;

- P9: of type E;
- P10: of type D or of type C,
- P11: of type E or of type D; or of type C and
- P12: of type C or of type D or of type E or of type F;
- at P6 and P7 also D-isomers being possible;

with the proviso that at least one of the amino acid residues is of type I.

17. (Original) Compounds according to claim 16 wherein the α -amino acid residues in position 1 – 12 of the chain Z are:

- P1: Leu; Thr; or Arg;
- P2: Arg; or Trp;
- P3: Leu;
- P4: Lys; hArg; (BA)G; or Gln;
- P5: Lys; Gln; hArg; or (PeA)G;
- P6: Arg, Trp, hArg; (EGU)G;
- (EA)G; (PrA)G; (PeA)G or (BA)G;
- P7: Arg; (PeA)G; or Val
- P8: Trp; or Bip;
- P9: Lys; Arg; or hArg;
- P10: Tyr;
- P11: Arg; or Tyr; and
- P12: Val; or Arg

with the proviso that

- the amino acid residue in P4 is (BA)G; and/or
- the amino acid residue in P5 is (PeA)G; and/or
- the amino acid residue in P6 is (EGU)G or (EA)G or (PrA)G or (PeA)G or (BA)G; and/or
- the amino acid residue in P7 is (PeA)G.

18. (Original) A compound of formula I according to claim 1 wherein the template is ^DPro-^LPro and the amino acid residues in position 1 – 12 are:

- P1: Leu;
- P2: Arg;
- P3: Leu;
- P4: Lys;
- P5: Lys;
- P6: (EA)G;
- P7: Arg;
- P8: Trp;
- P9: Lys;
- P10: Tyr;
- P11: Arg; and
- P12: Val.

19. (Original) A compound of formula Ia according to claim 1 wherein the template is ^DPro-^LPro and the amino acid residues in position 1 – 12 are:

- P1: Leu;
- P2: Arg;
- P3: Leu;
- P4: hArg;
- P5: hArg;
- P6: (EGU)G;
- P7: Arg;
- P8: Trp;
- P9: hArg;
- P10: Tyr;

Applicants: Vrijbloed et al.

Application No. 10/530,335

Response to Restriction/Election Requirement dated June 16, 2009

Page 27

- P11: Arg; and
- P12: Val.

20. (Original) A compound of formula I according to claim 1 wherein the template is ^DPro-^LPro and the amino acid residues in position 1 – 12 are:

- P1: Leu;
- P2: Arg;
- P3: Leu;
- P4: Lys;
- P5: Lys;
- P6: (PrA)G;
- P7: Arg;
- P8: Trp;
- P9: Lys;
- P10: Tyr;
- P11: Arg; and
- P12: Val.

21. (Original) A compound of formula I according to claim 1 wherein the template is ^DPro-^LPro; and the amino acid residues in position 1 – 12 are:

- P1: Leu;
- P2: Arg;
- P3: Leu;
- P4: Lys;
- P5: Lys;
- P6: (BA)G;
- P7: Arg;
- P8: Bip;

- P9: Lys;
- P10: Tyr;
- P11: Arg; and
- P12: Val.

22. (Original) A compound of formula I according to claim 1 wherein the template is ^DPro-^LPro and the amino acid residues in position 1 – 12 are:

- P1: Leu;
- P2: Arg;
- P3: Leu;
- P4: (BA)G;
- P5: Lys;
- P6: (BA)G;
- P7: Arg;
- P8: Bip;
- P9: Lys;
- P10: Tyr;
- P11: Arg; and
- P12: Val.

23. (Original) A compound of formula I according to claim 1 wherein the template is ^DPro-^LPro and the amino acid residues in position 1 – 12 are:

- P1: Leu;
- P2: Arg;
- P3: Leu;
- P4: Lys;
- P5: Lys;
- P6: (PrA)G;

Applicants: Vrijbloed et al.

Application No. 10/530,335

Response to Restriction/Election Requirement dated June 16, 2009

Page 29

- P7: Arg;
- P8: Bip;
- P9: Lys;
- P10: Tyr;
- P11: Arg; and
- P12: Val.

24. (Original) A compound of formula I according to claim 1 wherein the template is ^DPro-^LPro and the amino acid residues in position 1 – 12 are:

- P1: Arg;
- P2: Trp;
- P3: Leu;
- P4: Lys;
- P5: Lys;
- P6: Arg;
- P7: (PeA)G;
- P8: Trp;
- P9: Lys;
- P10: Tyr;
- P11: Tyr; and
- P12: Val.

25. (Original) A compound of formula I according to claim 1 wherein the template is ^DPro-^LPro and the amino acid residues in position 1 – 12 are:

- P1: Arg;
- P2: Trp;
- P3: Leu;
- P4: Gln;

Applicants: Vrijbloed et al.

Application No. 10/530,335

Response to Restriction/Election Requirement dated June 16, 2009

Page 30

- P5: (PeA)G;
- P6: Arg;
- P7: Arg;
- P8: Trp;
- P9: Lys;
- P10: Tyr;
- P11: Tyr; and
- P12: Arg.

26. (Original) A compound of formula I according to claim 1 wherein the template is ^DPro-^LPro and the amino acid residues in position 1 – 12 are:

- P1: Arg;
- P2: Trp;
- P3: Leu;
- P4: Lys;
- P5: (PeA)G;
- P6: Arg;
- P7: Arg;
- P8: Trp;
- P9: Lys;
- P10: Tyr;
- P11: Tyr; and
- P12: Val.

27. (Original) A compound of formula I according to claim 1 wherein the template is ^DPro-^LPro and the amino acid residues in position 1 – 12 are:

- P1: Thr;
- P2: Trp;

Applicants: Vrijbloed et al.

Application No. 10/530,335

Response to Restriction/Election Requirement dated June 16, 2009

Page 31

- P3: Leu;
- P4: Lys;
- P5: (PeA)G;
- P6: Arg;
- P7: Arg;
- P8: Trp;
- P9: Lys;
- P10: Tyr;
- P11: Tyr; and
- P12: Arg.

28. (Original) A compound of formula I according to claim 1 wherein the template is ^DPro-^LPro and the amino acid residues in position 1 – 12 are:

- P1: Arg;
- P2: Trp;
- P3: Leu;
- P4: Gln;
- P5: Lys;
- P6: Arg;
- P7: (PeA)G;
- P8: Trp;
- P9: Lys;
- P10: Tyr;
- P11: Tyr; and
- P12: Arg.

29. (Original) A compound of formula I according to claim 1 wherein the template is ^DPro-^LPro and the amino acid residues in position 1 – 12 are:

Applicants: Vrijbloed et al.

Application No. 10/530,335

Response to Restriction/Election Requirement dated June 16, 2009

Page 32

- P1: Thr;
- P2: Trp;
- P3: Leu;
- P4: Lys;
- P5: (PeA)G;
- P6: Arg;
- P7: Arg;
- P8: Trp;
- P9: Lys;
- P10: Tyr;
- P11: Tyr; and
- P12: Arg.

30. (Original) Enantiomers of the compounds of formula I as defined in claim 1.

31-32. (Cancelled)

33. (Previously presented) A pharmaceutical composition containing a compound according to claim 1 and a pharmaceutically inert carrier.

34. (Original) Compositions according to claim 33 in a form suitable for oral, topical, transdermal, injection, buccal, transmucosal, pulmonary or inhalation administration.


35. (Previously presented) Compositions according to claim 33 in form of tablets, dragees, capsules, solutions, liquids, gels, plaster, creams, ointments, syrup, slurries, suspensions, spray, nebuliser or suppositories.

36. (Currently amended) ~~The use of compounds according to claim 1 for the manufacture of a medicament~~ A method for treating or preventing infections or diseases related to such infections, which comprises administering to a patient in need of such treatment or prevention an effective amount of a compound according to claim 1, said disease being in particular Cystic Fibrosis.


37. (Currently amended) ~~The use of compounds according to claim 1 as disinfectants or preservatives for~~ A method for disinfecting or preserving foodstuffs, cosmetics, medicaments and other nutrient-containing materials which comprises adding to such foodstuffs, cosmetics, medicaments and other nutrient-containing materials an effective amount of a compound according to claim 1.

38. (Previously presented) A process for the manufacture of compounds according to claim 1 which process comprises


- (a) coupling an appropriately functionalized solid support with an appropriately N-protected derivative of that amino acid which in the desired end-product is in position 5, 6 or 7, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
- (b) removing the N-protecting group from the product thus obtained;
- (c) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is one position nearer the N-terminal amino acid residue, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
- (d) removing the N-protecting group from the product thus obtained;
- (e) repeating steps (c) and (d) until the N-terminal amino acid residue has been introduced;
- (f) coupling the product thus obtained with a compound of the general formula



wherein



is as defined above and X is an N-protecting group or, if



is to be group (a1) or (a2), above, alternatively

(fa) coupling the product obtained in step (e) with an appropriately N-protected derivative of an amino acid of the general formula



wherein B and A are as defined above, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

(fb) removing the N-protecting group from the product thus obtained; and

(fc) coupling the product thus obtained with an appropriately N-protected derivative of an amino acid of the above general formula IV and, respectively, III, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

(g) removing the N-protecting group from the product obtained in step (f) or (fc);


(h) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is in position 12, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

(i) removing the N-protecting group from the product thus obtained;


- (j) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is one position farther away from position 12, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
- (k) removing the N-protecting group from the product thus obtained;
- (l) repeating steps (j) and (k) until all amino acid residues have been introduced;
- (m) if desired, selectively deprotecting one or several protected functional group(s) present in the molecule and appropriately substituting the reactive group(s) thus liberated;
- (o) detaching the product thus obtained from the solid support;
- (p) cyclizing the product cleaved from the solid support;
- (q) if desired, forming one or two interstrand linkage(s) between side-chains of appropriate amino acid residues at opposite positions of the β -strand region;
- (r) removing any protecting groups present on functional groups of any members of the chain of amino acid residues and, if desired, any protecting group(s) which may in addition be present in the molecule;
- (s) if desired guanidinyllating any side-chain amino group present in the chain of amino acid residues; and
- (t) if desired, converting the product thus obtained into a pharmaceutically acceptable salt or converting a pharmaceutically acceptable, or unacceptable, salt thus obtained into the corresponding free compound of formula I or into a different, pharmaceutically acceptable, salt.

39. (Previously presented) A process for the manufacture of compounds according to claim 1 which process comprises


- (a') coupling an appropriately functionalized solid support with a compound of the general formula



wherein




is as defined above and X is an N-protecting group or, if



is to be group (a1) or (a2), above, alternatively

(a'a) coupling said appropriately functionalized solid support with an appropriately N-protected derivative of an amino acid of the general formula



wherein B and A are as defined above, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

(a'b) removing the N-protecting group from the product thus obtained; and

(a'c) coupling the product thus obtained with an appropriately N-protected derivative of an amino acid of the above general formula IV and, respectively, III, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

(b') removing the N-protecting group from the product obtained in step (a') or (a'c);

(c') coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is one position nearer the N-terminal amino acid residue, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

- (d') removing the N-protecting group from the product thus obtained;
- (e') coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is one position farther away from position 12, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
- (f') removing the N-protecting group from the product thus obtained;
- (g') repeating steps (e') and (f') until all amino acid residues have been introduced;
- (h') if desired, selectively deprotecting one or several protected functional group(s) present in the molecule and appropriately substituting the reactive group(s) thus liberated;
- (i') detaching the product thus obtained from the solid support;
- (j') cyclizing the product cleaved from the solid support;
- (k') if desired forming one or two interstrand linkage(s) between side-chains of appropriate amino acid residues at opposite positions of the β -strand region;
- (l') removing any protecting groups present on functional groups of any members of the chain of amino acid residues and, if desired, any protecting group(s) which may in addition be present in the molecule;
- (m') if desired guanidinylating any side-chain amino group present in the chain of amino acid residues; and
- (n') if desired, converting the product thus obtained into a pharmaceutically acceptable salt or converting a pharmaceutically acceptable, or unacceptable, salt thus obtained into the corresponding free compound of formula I or into a different, pharmaceutically acceptable, salt.

40. (Previously presented) A process according to claim 38 but wherein an amino acid residue of type I or K is introduced by coupling with a leaving group-containing acetylating agent, followed by nucleophilic displacement with an amine of the formula H_2NR^{86} and, respectively, H_2NR^{87} which, if necessary, is appropriately protected.

41. (Previously presented) A process according to claim 40 wherein said leaving group-containing acetylating agent is bromo, chloro or iodo acetic acid.
42. (Previously presented) A modification of the process according to claim 38 for the manufacture of compounds according to claim 30 in which enantiomers of all chiral starting materials are used.
43. (Previously presented) A process according to claim 39 but wherein an amino acid residue of type I or K is introduced by coupling with a leaving group-containing acetylating agent, followed by nucleophilic displacement with an amine of the formula H_2NR^{86} and, respectively, H_2NR^{87} which, if necessary, is appropriately protected.
44. (Previously presented) A process according to claim 43 wherein said leaving group-containing acetylating agent is bromo, chloro or iodo acetic acid.
45. (Previously presented) A modification of the process according to claim 39 for the manufacture of compounds according to claim 30 in which enantiomers of all chiral starting materials are used.
46. (New) A method according to claim 36 wherein said disease is Cystic Fibrosis.